Clovis, Genentech study rociletinib/atezolizumab combination; assumed terminated
Clovis Oncology Inc. and Genentech Inc. agreed to study a combination of the former's rociletinib and latter's atezolizumab in a Phase Ib/II trial in advanced or metastatic EGFR-mutant-positive non-small cell lung cancer (NSCLC).
- Intra-Biotech Deal
- Trial Collaborations
- R&D (No Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.